Wednesday October 21, 2020

Medicines boss: Costly new cancer drugs not working

Just one in 20 new cancer drugs assessed for the Irish market since the beginning of 2016 were considered value for money, according to a new assessment by the NCPE

Susan Mitchell

Deputy Editor and Health Editor

15th October, 2017
Professor Michael Barry, heads up the National Centre for Pharmacoeconomics Pic:

Most new cancer drugs are not worth the money being sought by pharmaceutical companies, the head of the state’s medicines watchdog has said in a stark assessment.

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), said the state was funding cancer drugs that cost anywhere between €50,000 and €100,000 per patient per year that “very often only prolong life by a few months – if even [that]”.


Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

The state’s National Cyber Security Centre is constantly dealing with suspected attacks and urgently needs more resources

Michael Brennan | 1 month ago

We are far less reliant on the UK as a trading partner now than in previous decades — our focus needs to switch to the many challenges and opportunities of the future

Neale Richmond | 1 month ago

Covid-19 and an economic crisis are exacerbating the trauma of this month’s explosion, writes a Concern worker on the ground

Dom Hunt | 1 month ago